All News

A recap of the FDA submissions and regulatory decisions in urology from April 2026.

In this episode, host Adam B. Weiner, MD, is joined by Maarten Albersen, MD, PhD, for a focused discussion on the evolving molecular landscape of penile cancer.

The FDA Oncologic Drugs Advisory Committee voted 7-1-1 in support of a favorable risk-benefit profile for capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC.

Findings from the HIFI-2 study suggest that salvage HIFU provides meaningful mid-term oncologic control with an acceptable safety profile in patients with localized prostate cancer recurrence after radiotherapy.

The phase 2 trial will assess the safety and efficacy of ViXe, a product designed to deliver botulinum toxin directly into the bladder wall.

Neoadjuvant sacituzumab govitecan plus pembrolizumab yielded a clinical complete response rate of 39%, supporting the potential for bladder preservation.

In this episode, Adam B. Weiner, MD, sits down with Giorgio Gandaglia, MD, to discuss the ongoing controversy surrounding pelvic lymph node dissection in prostate cancer.

Data from the CANOPY trial showed promising activity and manageable safety with cabozantinib plus nivolumab in mCRPC.

Phase 3 LITESPARK-012 shows adding belzutifan or quavonlimab to pembrolizumab-lenvatinib fails to boost survival in first-line advanced clear cell RCC.

The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of JANX014 in patients with mCRPC.

The FDA granted priority review to EV plus pembrolizumab as a perioperative regimen for cisplatin-eligible MIBC based on KEYNOTE-B15 data showing a 47% reduction in EFS events, a 35% reduction in the risk of death, and a pCR rate of 55.8% vs 32.5% with standard chemotherapy.

"Parastomal hernia repair can be performed either open or robotically, according to the surgeon’s preference. The 2 mainstays of repair are the keyhole and intraperitoneal Sugarbaker repairs," Wyre writes.

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, is joined by Dr. Alfonso Gomez de Liaño Lista for a timely discussion on a practice-changing development in muscle-invasive bladder cancer: the phase 3 KEYNOTE-B15 trial.

In this first installment of a 2-part interview, guideline chair professor Axel Heidenreich outlines key updates in the management of testicular cancer, with a strong focus on deintensification.

Adding pembrolizumab to trimodality therapy demonstrated encouraging activity in patients with muscle-invasive bladder cancer.

The assay is designed to detect multiple cancers, including prostate, bladder, and kidney cancer, through a simple, non-invasive urine sample.

Pearlman and Rodriguez explore the persistent disconnect between medical treatment and quality-of-life conversations, particularly when it comes to sexual health.

In this episode of The UroOnc Minute, Adam B. Weiner, MD, speaks with Alexander Light, MBBS, about evolving strategies for salvage treatment in patients with radiorecurrent prostate cancer.

In this interview, Brett Trockman, MD, FACS, details how shifting guideline recommendations and expanding treatment options are allowing for more personalized approaches to sacral neuromodulation.

A central theme of the conversation is the importance of practicing at the top of one’s license.

Treatment with 177Lu-PSMA-617 may durably delay disease progression compared with deferred ADT in men with oligometastatic hormone-sensitive prostate cancer.

Investigators in the BioFront trial are evaluating whether CBM588 enhances the efficacy of immune checkpoint inhibitors in renal cell carcinoma.